A multicenter, randomized, double-blind, placebo controlled, parallel group, adaptive design, efficacy and tolerability study of 4 fixed doses of DVS-233 [desvenlafaxine] in adult outpatients with fibromyalgia syndrome
Phase of Trial: Phase II/III
Latest Information Update: 01 Jan 2017
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Fibromyalgia
- Focus Therapeutic Use
- Sponsors Wyeth
- 12 Feb 2007 Status change
- 02 Feb 2007 New trial centres added.
- 08 Oct 2006 New trial record.